Radiation Oncology
Expert insights on radiation treatment planning, techniques, toxicity management, and multimodal cancer care.
Recent Discussions
Would you treat bilateral synchronous breast cancers in prone position?
I have done this one time in past and fused two the CT scans to ensure that based on anatomy there is significant gap between two fields
In a patient who requires prostate cytoreduction prior to EBRT or brachytherapy, do you include a 5-alpha reductase inhibitor in your ADT regimen?
This is a great question. Although 5-aplha reductase inhibitors do shrink the prostate, there is little data reporting on its use prior to RT. Jethwa et al (J of Contem Brachytherapy 2016 Oct; 8(5): 371–378.) evaluated factors that impacted decrease in prostate volume and the initial prostate volu...
Would you recommend adjuvant chemoradiation for T1N0 gastric adenocarcinoma status post R0 resection but no D2 lymph node dissection?
I would not recommend adjuvant chemoradiation for a patient with an R0 resection for a T1N0 gastric adenocarcinoma even though a D2 dissection was not performed. If the patient had high risk factors, adjuvant chemotherapy may be appropriate in view of distant metastasis rates of ~ 30% with T1-2N0 le...
Would you offer RT to a large infiltrative renal metastasis in a patient with minimal other systemic disease?
With modern treatment delivery techniques, there really are no longer any regions in the body in which a potentially therapeutic dose of radiation cannot be delivered, and durable local control can be achieved in locations where this was not possible in the past. Nevertheless, as the question implie...
Is treating high-risk prostate cancer with trimodality therapy safe for a patient who remains on anti-PD1 therapy for metastatic melanoma?
More important question is do we need to treat patient with triple modality for high risk disease if they have metastatic melanoma as outcome would be dictated by metastatic disease
What is your standard dose for total skin irradiation in a mycosis fungoides patient?
Our standard has been to do the low-dose 12 Gy TSE regimen as it still has good overall response rates with low toxicity.https://www.ncbi.nlm.nih.gov/pubmed/25476993https://www.ncbi.nlm.nih.gov/pubmed/28843374I asked @Dr. First Last to weigh in on this and he agrees that 12 Gy is the standard.
Do you do recommend further mediastinal staging for patients with SCLC or inoperable NSCLC with N1 disease on PET?
I would usually request an EBUS. PET is really outstanding for staging of all lung cancer, but sensitivities in the 90+%, but it will occasionally miss the small nodes of the mediastinum. In SCLC, with a N1 node "with high SUV" the pretest probability of having an N2 node is quite high, so it would ...
How do you manage gastroesophageal junction cancer after resection with a positive circumferential surgical margin when no neoadjuvant treatment has been given?
Fortunately this is not a common occurrence in my practice. However, prior to the wide acceptance of preoperative RT/chemo for esophageal cancer it was more common. I don't think the data base is very good for answering the question, but I have usually treated these patients with essentially the sam...
How would you manage a small to medium sized but unresectable nodal recurrence within the original treatment volume for a head and neck squamous cell carcinoma?
There are a lot of points to consider before you can make this decision: what is the time interval from prior RT? what dose was received to this node from prior RT? what are the critical organs at risk if you were to treat this node? why is this node considered unresectable? how large is the nodal ...
How do you manage sarcomas of the hand or the feet?
This is a very difficult question. Please see my answer to the previous Mednet question: How would you optimize patient set-up and planning for the post-operative treatment of a distal lower extremity sarcoma? for general information on how I approach set-up for these patients.Hand and feet sarcomas...